Evidence map›Paper›PMID 38499653›Full record

ArticleMolecular psychiatry2024

Scanning ultrasound-mediated memory and functional improvements do not require amyloid-β reduction.

Gerhard Leinenga, Xuan Vinh To, Liviu-Gabriel Bodea, Jumana Yousef, Gina Richter-Stretton, Tishila Palliyaguru, Antony Chicoteau, Laura Dagley, Fatima Nasrallah, Jürgen Götz

Erratum issuedAbstract read
In one paragraph

Article in Molecular psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Emerging Wearable Acoustic Sensing Technologies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  12. Article
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Gerhard LeinengaClem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.
Xuan Vinh ToQueensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.
Liviu-Gabriel BodeaClem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.
Jumana YousefProteomics Facility, Advanced Technology and Biology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Gina Richter-StrettonClem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0002-8714-5776
Tishila PalliyaguruClem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.
Antony ChicoteauClem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.
Laura DagleyProteomics Facility, Advanced Technology and Biology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Fatima NasrallahQueensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia.
Jürgen GötzClem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, QLD, Australia. j.goetz@uq.edu.au.ORCID 0000-0001-8501-7896

Funding

Alzheimer's Association 22-AAIIA-965230Department of Health | National Health and Medical Research Council (NHMRC) GA39196Department of Health | National Health and Medical Research Council (NHMRC) GNT1145580Department of Health | National Health and Medical Research Council (NHMRC) GNT1176326
6 · The paper itself

Abstract

A prevalent view in treating age-dependent disorders including Alzheimer's disease (AD) is that the underlying amyloid plaque pathology must be targeted for cognitive improvements. In contrast, we report here that repeated scanning ultrasound (SUS) treatment at 1 MHz frequency can ameliorate memory deficits in the APP23 mouse model of AD without reducing amyloid-β (Aβ) burden. Different from previous studies that had shown Aβ clearance as a consequence of blood-brain barrier (BBB) opening, here, the BBB was not opened as no microbubbles were used. Quantitative SWATH proteomics and functional magnetic resonance imaging revealed that ultrasound induced long-lasting functional changes that correlate with the improvement in memory. Intriguingly, the treatment was more effective at a higher frequency (1 MHz) than at a frequency within the range currently explored in clinical trials in AD patients (286 kHz). Together, our data suggest frequency-dependent bio-effects of ultrasound and a dissociation of cognitive improvement and Aβ clearance, with important implications for the design of trials for AD therapies.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBlood-Brain BarrierDisease Models, AnimalMagnetic Resonance ImagingMice, TransgenicAmyloid beta-Protein PrecursorAnimalsBrainCognitionMaleMemoryMemory DisordersMicePlaque, AmyloidAmyloid beta-PeptidesAmyloid beta-Protein Precursor

Identifiers

PMID38499653
PMCPMC11412907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.